Skip to main content
OpenTrials
Completed

NCT Number: NCT02952755

Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20162 in Healthy Volunteers

A randomized, open label, crossover study to explore drug-drug interactions between DWC20155 / DWC20156 and DWC20162 in Healthy Volunteers

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

19 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Bundang CHA Medical Center

Gyunggi, South Korea

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Accepts healthy volunteers

Exclusion criteria

  • Who has allergy to investigational product

Treatment and study plan

Co-administration of DWC20155/DWC20156

Drug

DWC20162

Drug

Primary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Time frame: 0 ~ 24 hours

  2. Area under the time versus plasma concentration curve (AUC)

    Time frame: 0 ~ 24 hours

Sponsors and collaborators

Lead sponsor

Daewoong Pharmaceutical Co. LTD.

Industry

Registry information

Official study title

A Randomized, Open-label, Crossover Study to Explore Drug-drug Interactions Between DWC20155 / DWC20156 and DWC20162 in Healthy Volunteers

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Nov 2, 2016
Registry last updated
Feb 16, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.